Sara M. Tolaney, MD, MPH | Authors


The monarcHER Trial in Advanced HR+, HER2+ Breast Cancer

December 13, 2019

Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.

Evaluating the Role of Neoadjuvant Endocrine Therapy in Breast Cancer

August 01, 2019

Sara M. Tolaney, MD, MPH, discusses the evolving role of neoadjuvant endocrine therapy in the breast cancer space. She says there is particular interest in using this therapy in patients with HER2-positive and triple-negative breast cancer, but it can be more challenging in patients with ER-positive disease.